A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

BACKGROUND: Presently, few options are available for refractory colorectal cancer (CRC). O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation is a frequent and early event in CRC tumourigenesis. This epigenetic silencing is a predictor of response to the alkylating drug temozolomide i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Calegari, M A, Inno, A, Monterisi, S, Orlandi, A, Santini, D, Basso, M, Cassano, A, Martini, M, Cenci, T, de Pascalis, I, Camarda, F, Barbaro, B, Larocca, L M, Gori, S, Tonini, G, Barone, C
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482728/
https://ncbi.nlm.nih.gov/pubmed/28427088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.109
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars